- Laura J. BalcerAffiliated withDivision of Neuro-ophthalmology, Department of Neurology and Ophthalmology, University of Pennsylvania School of Medicine
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Intravenous methylprednisolone sodium succinate (1 g intravenously [IV] per day for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days) with a 4-day taper (20 mg on day 1, 10 mg on days 2 and 4).
Interferon beta 1-a, which has been demonstrated to significantly reduce the 3-year probability of the development of CDMS and the development of clinically silent MRI lesions in high-risk patients with acute optic neuritis, should be considered following IV methylprednisolone treatment (30 mg intramuscularly [IM] weekly).
In monosymptomatic patients with fewer than two white matter lesions by MRI, and in patients for whom a diagnosis of CDMS has been established, treatment with IV methylprednisolone followed by oral prednisone (as outlined), should be considered on an individual basis and may hasten visual recovery, but has not been demonstrated to affect long-term visual outcome. In all cases of typical acute monosymptomatic demyelinating optic neuritis, oral prednisone alone at a dose of 1 mg/kg per day, without prior treatment with IV methylprednisolone (1 g per day for 3 days), may increase the risk for recurrent optic neuritis, and should be avoided.
- Optic neuritis
Current Treatment Options in Neurology
Volume 3, Issue 4 , pp 389-398
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Division of Neuro-ophthalmology, Department of Neurology and Ophthalmology, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3 East Gates, 19104, Philadelphia, PA, USA